Idioma:

HISTOPATHOLOGIC FEATURES OF CENTRAL GIANT CELL GRANULOMA TREATED BY DENOSUMAB

DOS SANTOS MOREIRA, FERNANDA ; DE OLIVEIRA, THIAGO BUENO ; COSTA, FELIPE D'ALMEIDA ; AYRES, FREDERICO LOUVEIRA ; KOWALSKI, LUIZ PAULO ; DE ABREU ALVES, FÁBIO

Oral surgery, oral medicine, oral pathology and oral radiology, 2020-01, Vol.129 (1), p.e128-e128 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por

Título:
HISTOPATHOLOGIC FEATURES OF CENTRAL GIANT CELL GRANULOMA TREATED BY DENOSUMAB
Autor: DOS SANTOS MOREIRA, FERNANDA ; DE OLIVEIRA, THIAGO BUENO ; COSTA, FELIPE D'ALMEIDA ; AYRES, FREDERICO LOUVEIRA ; KOWALSKI, LUIZ PAULO ; DE ABREU ALVES, FÁBIO
É parte de: Oral surgery, oral medicine, oral pathology and oral radiology, 2020-01, Vol.129 (1), p.e128-e128
Descrição: Central giant cell granulomas (CGCGs) are benign lesions of the jaws. Surgical management may cause significant morbidity, and noninvasive therapies such as intralesional corticoid, calcitonin, and, more recently, denosumab have been used as an option. The study aimed to describe histopathologic characteristics of CGCGs treated by denosumab. A 39-year-old man was referred to treat a CGCG. The imaginological examinations showed an extensive osteolytic lesion affecting the left maxilla. Tumor board evaluation proposed systemic therapy with denosumab. Four doses of denosumab (120 mg) were administered during the first month followed by 2 monthly doses (Thomas, 2010). After 3 months, there was facial edema, and the patient refused follow-up. Surgical treatment was performed, and the histopathologic examination showed a granulation tissue in a central region and a formation of mature bone trabeculae in the periphery. Typical areas of CGCG were not observed. This report shows that denosumab inhibits the giant cells of CGCG.
Editor: Elsevier Inc
Idioma: Inglês

Voltar para lista de resultados

Anterior Resultado 8 Avançar Ir para próxima página